|
|
Weekly Digest
July 21, 2026
Volume 4, Issue 3
|
|
What’s Inside This Week
The most consequential challenge to DSHEA in years arrived this week when the American College of Physicians published a position paper in Annals of Internal Medicine calling on Congress to replace the statute’s food-based framework with pharmaceutical-style premarket approval, a proposal that the Natural Products Association, the Council for Responsible Nutrition, and the American Herbal Products Association all moved swiftly to reject. That fight lands against a mid-year regulatory picture in which FDA is advancing mandatory GRAS notification, reconsidering the boundaries of what counts as a dietary ingredient, and pressing risk-based enforcement under a MAHA-shaped agenda. Meanwhile, state law continues to generate the industry’s most immediate compliance pressure, with New Hampshire enacting a liquor-law exemption that protects alcohol-based herbal tinctures and Missouri hemp businesses filing a federal suit to block a statute they argue leaves them no lawful path forward. On the science and ingredient side, a first-of-its-kind Akkermansia strain cleared FDA’s new dietary ingredient pathway, ashwagandha stakeholders assembled safety evidence ahead of a possible EFSA review, and new cohort data linked vitamin C status to brain structure in older adults.
|
|
|
|
DSHEA Under Pressure
|
|
Nutritional Outlook | July 14, 2026
The ACP’s ten-point proposal would require Congress to amend DSHEA so that all dietary supplements, including products already on the market, undergo evidence-based FDA review, registration, and approval, alongside United States Pharmacopeia quality standards. The paper argues that treating supplements as a subcategory of food places too much weight on postmarket surveillance to catch adulterated or mislabeled products. It represents the most direct institutional challenge to DSHEA’s core architecture in recent memory.
|
|
|
NutraIngredients | July 17, 2026
CRN, AHPA, and NPA each rejected the premarket approval proposal while acknowledging shared ground on enforcement, arguing that adulteration and illegal disease claims are already prohibited under existing law. NPA president Daniel Fabricant noted that products spiked with active pharmaceutical ingredients are illegal drugs rather than dietary supplements. AHPA’s Graham Rigby stressed that no comparable premarket approval system exists for conventional foods or cosmetics.
|
|
|
|
|
FDA & Regulatory Action
|
|
NutraIngredients | July 17, 2026
The first half of 2026 delivered active oversight rather than the deregulatory golden age parts of the industry expected, with the Office of Dietary Supplement Programs now housed inside FDA’s new Office of Food Chemical Safety, Dietary Supplements and Innovation. On July 3, the White House regulatory agenda confirmed a proposed rule requiring mandatory GRAS notices, tentatively slated for December 2026. FDA’s continuing reconsideration of what qualifies as a dietary substance under section 201(ff)(1) remains the most consequential open question for ingredient innovation.
|
|
|
Nutritional Outlook | July 17, 2026
Maypro’s Akkermansia muciniphila ingredient completed FDA’s new dietary ingredient notification process as Notification #1468, the first human-intestinal-origin strain of the species to do so. The NDI pathway is a premarket safety filing required for ingredients not marketed in the United States before October 1994, and completion signals only that FDA did not object to the safety evidence submitted. It establishes useful regulatory precedent as the microbiome ingredient category matures under DSHEA’s existing framework.
|
|
|
|
|
State Law & Litigation
|
|
Nutritional Outlook | July 14, 2026
Governor Kelly Ayotte signed SB 524, exempting alcoholic preparations not fit for use as a beverage, explicitly including DSHEA-defined dietary supplements, from state liquor regulation effective January 1, 2027. The fix resolves a New Hampshire Liquor Commission interpretation that had forced alcohol-based tinctures off retail shelves in late 2025. AHPA, which organized the legislative response, called the outcome a permanent protection for consumer access to traditional herbal liquid extracts.
|
|
|
Nutritional Outlook | July 20, 2026
A coalition including the MoHemp Trade Association filed suit in federal court on July 16 to stop a Missouri statute that simultaneously treats hemp-derived cannabinoid products as both hemp and marijuana, requiring licenses the state has already issued to capacity. The complaint raises void-for-vagueness, dormant Commerce Clause, and Farm Bill preemption claims. For supplement brands, the case underscores how state ingredient classification fights can strand lawful products with no compliance pathway.
|
|
|
|
|
Botanicals & Global Regulation
|
|
NutraIngredients | July 16, 2026
Industry scientists and regulatory experts met at the European Parliament on July 14 to launch Safeguard Ashwagandha, presenting a review of 131 clinical trial reports and toxicological assessments ahead of a possible EFSA Article 8 review. Speakers argued that a ban would drive consumers toward less-studied adaptogens and unregulated online channels. US stakeholders are watching closely, since European determinations on botanical safety frequently become de facto global standards.
|
|
|
|
|
Science & Industry
|
|
Nutritional Outlook | July 17, 2026
A cross-sectional PLOS ONE study of 2,044 Japanese adults over age 64 found plasma vitamin C levels significantly associated with gray and white matter volume ratios and with default mode network connectivity, independent of vascular risk factors. The authors describe the findings as hypothesis-generating and call for longitudinal work. For formulators, the results reinforce plasma ascorbate as a defensible biomarker while keeping structure and function claims well short of cognitive benefit language.
|
|
|
Nutritional Outlook | July 20, 2026
A review in Life proposes a sleep-glymphatic-vascular continuum in cerebral small vessel disease and evaluates tocotrienols as a biologically plausible but unproven nutritional intervention. The authors are explicit that most mechanistic data come from rodent models and that no trial has paired tocotrienol supplementation with glymphatic-specific endpoints. The paper is a useful reminder that mechanistic plausibility alone does not substantiate claims under FTC and FDA standards.
|
|
|
Nutritional Outlook | July 17, 2026
CRN released the seven-presentation lineup for its 2026 Innovation Exchange, running October 6 through 8 in Carlsbad, California, with topics spanning women’s health, microbiome science, and pharmacokinetic evidence standards for botanicals. A steering committee drawn from Better Being, GNC, Kenvue, Nature’s Way, and Unilever selected the slate. The programming’s explicit framing around marketing compliance reflects how closely claim substantiation now tracks regulatory risk.
|
|
|
Your Voice Matters
The American College of Physicians has asked Congress to replace DSHEA’s framework with pharmaceutical-style premarket approval. Consumers, practitioners, and industry stakeholders who value continued access to dietary supplements should make their position known to their representatives now, while the proposal is still shaping the debate.
|
|
|
DSHEA Preservation Alliance
Defending the Dietary Supplement Health and Education Act of 1994
|
|
